More than 50% of infections are classified as polyclonal infection for msp1 against one-third percent for msp2. The high diversity reported may reinforce the use of msp1 and msp2 to distinguish recrudescent from new infection in antimalarial efficacy trials in Burkina Faso. This evidence concerns the gene ATAD1 and infection.